Therefore, dysregulation of BA metabolism can also affect the function of BSEP through FXR and upregulate the expression of efflux transporter genes, MDR1 and MRP1, which can cause HCC cells to pump regorafenib out of the cell more quickly, reduce intracellular drug concentration, and cause drug insensitivity. This evidence concerns the gene ABCB1 and hepatocellular carcinoma.